יחס חוב לטווח ארוך להון CARGO Therapeutics, Inc (CRGX)
Political risks and restrictions on the cross-border movement of biodata are hindering the development of CARGO Therapeutics (CRGX). CARGO Therapeutics (CRGX) is resisting the expansion of industry behemoths seeking dominance in the gene therapy segment. Unique patents for combating resistant tumors provide a competitive advantage, while the 0.00 metric characterizes the issuer's financial condition. The price trend shown in this chart visualizes the value dynamics of the assets of this developer of innovative cancer treatments.
פילוחים אנליטיים של חברת CARGO Therapeutics
Developing cell therapies to combat resistant forms of cancer requires significant capital expenditures. This long-term debt financial leverage ratio measures the proportion of liabilities with a maturity exceeding one year relative to equity. It determines the extent of CARGO Therapeutics (CRGX) dependence on external borrowing for long-term planning. Analysis of this chart's dynamics allows for an assessment of the risks of an overleveraged balance sheet. A low value confirms financial stability and investment security.